Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis
Crossref DOI link: https://doi.org/10.1007/s13555-022-00830-x
Published Online: 2022-10-08
Published Print: 2022-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shao, Shuai
Wang, Gang http://orcid.org/0000-0002-5842-8080
Text and Data Mining valid from 2022-10-08
Version of Record valid from 2022-10-08
Article History
Received: 15 July 2022
Accepted: 30 September 2022
First Online: 8 October 2022